OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that...
PALO ALTO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative...
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive...
Incumbent Board’s Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted...
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic...
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)...
Sales Focus Inc., the sales outsourcing pioneer, has released a comprehensive white paper, "How to Thrive in the Era of Virtual...
FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER...
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC...
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") is pleased to...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and...
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease...
Business Activity Index at 53.7%; New Orders Index at 53.7%; Employment Index at 51.5%; Supplier Deliveries Index at 49.5% TEMPE, Ariz., Dec....
Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo...
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Calgary, Alberta--(Newsfile Corp. - December 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, Pa. ,...